Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03504163
Title Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications
Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Recruiting Basking Ridge New Jersey 10065 United States Details
Memorial Sloan Kettering Monmouth (All Protocol Activities) Recruiting Middletown New Jersey 07748 United States Details
Memorial Sloan Kettering Bergen (All protocol activities) Recruiting Montvale New Jersey 07645 United States Details
Memorial Sloan Kettering Commack (All protocol activities) Recruiting Commack New York 11725 United States Details
Memorial Sloan Kettering West Harrison (All Protocol Activities) Recruiting Harrison New York 10604 United States Details
Memorial Sloan Kettering Cancer Center (All Protocol Activities) Recruiting New York New York 10065 United States Details
Memorial Sloan Kettering Nassau (All Protocol Activities) Recruiting Uniondale New York 11553 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field